Search the Newsreel

Anavex Life Sciences Faces September Board Vote as Blarcamesine Regulatory Strategy Advances

Researcher looking through microscope ©Michael J. Ermarth Anavex is asking shareholders to re-elect its six nominees at the September 24 annual meeting as activist investor PVG seeks board control during a leadership transition and a critical period for the company's CNS pipeline. Key Investor …

Anavex Life Sciences Highlights Highly Qualified Board and Decisive Actions to Create Long-Term Value for Stockholders

Anavex Life Sciences has filed definitive proxy materials for its 2026 Annual Meeting, urging stockholders to vote for its six director nominees. The company highlights its refreshed, independent Board, decisive actions to stabilize the company and advance its blarcamesine programs for CNS diseases. Anavex …

Anavex Life Sciences (NASDAQ:AVXL) Stock Crosses Above 50-Day Moving Average - What's Next?

Anavex Life Sciences (NASDAQ: AVXL) delays two 2026 quarterly SEC reports

Anavex Life Sciences (NASDAQ: AVXL) has announced delays in filing its quarterly reports for the periods ending March 31, 2026, and June 30, 2026. The delay for the June 30 report is attributed to an ongoing Special Committee review related to the termination of …

Anavex Life Sciences Corp (AVXL) Earnings Forecast: Future EPS & Revenue Growth Estimates

AVXL Financials: Revenue Breakdown, Margins & Competitor Comparison

This article provides a financial overview of Anavex Life Sciences Corp (AVXL), detailing its market capitalization, profitability margins, and a comparison with competitors AGEN and ZNTL. It highlights AVXL's current financial metrics such as its N/A gross, operating, and net margins, and a Return …

Anavex Life Sciences Corp. (AVXL) Stock Analysis: Exploring a Potential 509% Upside in Biotech

Anavex Life Sciences Corp. (AVXL) is highlighted as a biotech company with significant potential upside, driven by its lead drug candidate, ANAVEX 2-73, for CNS disorders like Alzheimer's and Rett syndrome. Despite current volatility and developmental-stage financial characteristics, analyst ratings suggest a 509.76% upside …

Anavex Life Sciences Corp. Revenue Breakdown – NASDAQ:AVXL

This article provides financial information for Anavex Life Sciences Corp. (NASDAQ: AVXL), including an overview of its financials, statements, statistics, dividends, earnings, and segment performance. It highlights the company's listing on the Nasdaq Stock Market and references data from ICE Data Services and FactSet.

Anavex Life Sciences Corp. (AVXL) Stock Price, News, Quote & History

Anavex Life Sciences Corp. (AVXL) is a biopharmaceutical company focused on developing treatments for neurodegenerative and rare diseases, including Alzheimer's and Parkinson's. Its lead drug candidate, ANAVEX 2-73 (blarcamesine), is in various clinical trials. The company's stock shows significant one-year and five-year declines, but …

Anavex Announces Board Refresh as It Seeks to Strengthen Governance and Advance Drug Pipeline

Woman looking through microscope ©The U.S. National Archives Anavex Life Sciences (NASDAQ:AVXL) has nominated two new independent directors as part of a broader board refresh ahead of its 2026 Annual Meeting, while outlining its strategy to stabilize leadership, defend against a proxy challenge, and …

Anavex Life Sciences Announces Plans to Refresh Board to Continue Overseeing Critical Progress and Stockholder Value Creation

Anavex Life Sciences announced plans to refresh its Board of Directors by nominating two new independent directors, Mr. Gautam Patel and Dr. Adrian Senderowicz, to stand for election at the 2026 Annual Meeting. This move is part of the company's strategy to enhance stockholder …

Promising Penny Stocks To Consider In August 2026

This article identifies three promising penny stocks for August 2026: Anavex Life Sciences (AVXL), Enovix (ENVX), and SES AI (SES). Each company operates in innovative sectors like biopharmaceuticals and advanced battery technology. While all three are pre-profitability and face typical penny stock challenges, they …

Anavex Life Sciences (AVXL) Projected to Release Earnings on Monday

[PREC14A] ANAVEX LIFE SCIENCES CORP. Preliminary Contested Proxy Statement

This is a preliminary contested proxy statement from Anavex Life Sciences Corp. (AVXL) outlining proposals for its 2026 Annual Meeting of Stockholders. The company is facing a proxy contest from PVG Group, which has nominated six candidates for the board, opposing the Executive Committee's …

Vanguard Capital Management (NASDAQ: AVXL) discloses 5.03% beneficial stake in Anavex

Vanguard Capital Management has disclosed a 5.03% beneficial stake in Anavex Life Sciences Corp (NASDAQ: AVXL), according to a recent Schedule 13G SEC filing. This stake amounts to 4,663,459 shares as of June 30, 2026, with Vanguard exercising sole voting power over 608,870 shares …

Anavex Life Sciences reports preliminary Q2 FY2026 net loss $5.3M, cash $127.4M

Anavex Life Sciences reported a preliminary net loss of $5.3 million for Q2 FY2026, or $0.06 per share, and held $127.4 million in cash and cash equivalents, which is expected to fund operations into mid-to-late fiscal 2028. The company is focusing on regulatory engagement …

Anavex Life Sciences Reports Preliminary Second Quarter 2026 Financial Results and Provides Business Update

Anavex Life Sciences reported preliminary financial results for its fiscal second quarter ended March 31, 2026, showing decreased net loss and operating expenses year-over-year. The company is focusing on advancing its lead compound ANAVEX®2-73 (blarcamesine) for early Alzheimer's disease, Rett syndrome, and Fragile X …

Anavex Life Sciences: Fiscal Q2 Earnings Snapshot

Anavex Life Sciences Corp. Revenue Breakdown – BX:12X1

This page from TradingView provides financial information for Anavex Life Sciences Corp. (BX:12X1) on the BX Swiss exchange. It includes an overview of financials, statements, statistics, dividends, earnings, and segment performance. The content primarily focuses on navigation and financial data categories rather than a …

Anavex Life Sciences Q2 Results: EPS beats estimates

Anavex expects $127M cash to fund operations into 2028

Anavex Life Sciences Corp (AVXL) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Anavex Life Sciences Corp (AVXL) regarding its dividend history and stock splits. It indicates that the company has not distributed any dividends over the past five years. The page also presents current stock performance data, market capitalization, and …

AVXL|Anavex Life Sciences Corp|Price:2.400|Chg%:-0.080

Anavex Life Sciences Corp. (AVXL) is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system diseases. The article provides an overview of the company's profile, including its core programs ANAVEX 2-73 and ANAVEX 3-71, and lists key executives and institutional shareholding …

Anavex Life Sciences Corp. Revenue Breakdown – SWB:12X1

This page provides financial information for Anavex Life Sciences Corp. (SWB:12X1) listed on the Stuttgart Stock Exchange. It offers an overview of the company's financials, including statements, statistics, dividends, earnings, and segment performance. The content is primarily a navigation hub to various financial data …

PVG targets full board replacement at Anavex Life Sciences (NASDAQ: AVXL)

PVG Asset Management Corporation and Patrick S. Adams are launching an activist proxy solicitation to replace the entire Board of Directors at Anavex Life Sciences (NASDAQ: AVXL) with six independent nominees during the 2026 annual meeting. The activist group, collectively owning 327,344 shares of …

Anavex Life Sciences submits compliance plan to Nasdaq after 10-Q delay

Anavex Life Sciences (AVXL) submitted a Compliance Plan to Nasdaq following a late Form 10-Q filing for the quarter ended March 31, 2026. The company aims to regain compliance with Nasdaq Rule 5250(c)(1) and seek reinstatement of its listing. While the deficiency notice does …

Anavex Life Sciences Corp. (NASDAQ:AVXL) Receives Average Rating of "Hold" from Brokerages